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Abstract
Background: The incidence of oropharyngeal squamous cell carcinoma (OPSCC) caused by oncogenic human
papillomavirus (HPV) is rising worldwide. HPV-OPSCC is commonly diagnosed by RT-qPCR of HPV E6 and E7
oncoproteins or by p16 immunohistochemistry (IHC). Droplet digital PCR (ddPCR) has been recently reported as
an ultra-sensitive and highly precise method of nucleic acid quantification for biomarker analysis. To validate the
use of a minimally invasive assay for detection of oncogenic HPV based on oropharyngeal swabs using ddPCR.
Secondary objectives were to compare the accuracy of ddPCR swabs to fresh tissue p16 IHC and RT-qPCR, and to
compare the cost of ddPCR with p16 IHC.
Methods: We prospectively included patients with p16+ oral cavity/oropharyngeal cancer (OC/OPSCC), and two
control groups: p16− OC/OPSCC patients, and healthy controls undergoing tonsillectomy. All underwent an
oropharyngeal swab with ddPCR for quantitative detection of E6 and E7 mRNA. Surgical specimens had p16 IHC
performed. Agreement between ddPCR and p16 IHC was determined for patients with p16 positive and negative
OC/OPSCC as well as for healthy control patients. The sensitivity and specificity of ddPCR of oropharyngeal swabs
were calculated against p16 IHC for OPSCC.
Results: 122 patients were included: 36 patients with p16+OPSCC, 16 patients with p16−OPSCC, 4 patients
with p16+OCSCC, 41 patients with p16−OCSCC, and 25 healthy controls. The sensitivity and specificity of
ddPCR of oropharyngeal swabs against p16 IHC were 92 and 98% respectively, using 20–50 times less RNA
than that required for conventional RT-qPCR. Overall agreement between ddPCR of tissue swabs and p16 of
tumor tissue was high at ĸ = 0.826 [0.662-0.989].
Conclusion: Oropharyngeal swabs analyzed by ddPCR is a quantitative, rapid, and effective method for
minimally invasive oncogenic HPV detection. This assay represents the most sensitive and accurate mode of
HPV detection in OPSCC without a tissue biopsy in the available literature.
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Background
Head and neck squamous cell carcinoma (HNSCC) is now
the fifth most common malignancy worldwide [1]. The
incidence of oropharyngeal squamous cell carcinoma
(OPSCC), a subsite of HNSCC, is rapidly increasing in
North America [2]. Although traditional risk factors for
HNSCC include smoking and alcohol use, the rising inci-
dence of OPSCC has been attributed largely to the Human
Papillomavirus (HPV) [3–6]. Determining HPV positivity is
of critical importance in the diagnosis and management of
OPSCC, as HPV positive tumours have unique pathologic
and clinical characteristics that have implications for prog-
nosis and treatment decisions [3, 7–10].
The gold standard for determining HPV status in
OPSCC is demonstration of oncogenic HPV DNA in
fresh tissue using real-time quantitative polymerase
chain reaction (RT-qPCR) [1, 11, 12]. Due to the high
cost and specialized equipment required for this method,
most centers have adopted p16 immunohistochemistry
(p16 IHC) as the preferred method of oncogenic HPV
detection, which has become the clinical standard. [13–17]
However, p16 IHC is an imperfect surrogate marker for
HPV-associated OPSCC. HPV infection is carcinogenic
through expression of oncogenic proteins E6 and E7
which cause multiple genetic and metabolic effects
within the cell, the most important of which is degrad-
ation of tumor suppressor genes including p53 and Rb
[18]. By a separate pathway, this results in downstream
overexpression of p16. Because p16 overexpression can
occur through HPV-independent pathways, p16 IHC
can lead to false positives, which could result in errone-
ous de-intensification of treatment. Although RT-PCR
of E6 and E7 can circumvent the limitations of p16
IHC, it also requires adequate nucleic acid sample
generally only attainable from tissue biopsy.
Droplet digital polymerase chain reaction (ddPCR) is a
relatively novel technique with potential applications for
HPV detection in OPSCC. ddPCR is the most accurate
and sensitive mode of measuring target nucleic acids
quantitatively in the available literature [19]. ddPCR
involves partitioning a single nucleic acid sample in up to
20,000 discrete water-in-oil droplets and performing PCR
analysis on each droplet independently, with the results
reported digitally and quantitatively. This technique quan-
tifies the absolute amount of target nucleic acid present
with greater precision and reproducibility than RT-qPCR
[20–23]. ddPCR has been used to quantify gene expres-
sion with extremely low copy number [24, 25], and has
demonstrated better diagnostic performance in biomarker
analysis than other molecular techniques. [22, 26, 27] One
study made use of ddPCR for detection of oncogenic E6/
E7 mRNA in fresh tissue OPSCC specimens and found
100% sensitivity compared to p16 IHC using target RNA
20–50 times lower than reported for RT-qPCR [28].
Because of the accuracy and ultra-sensitivity of ddPCR
for identification of oncogenic HPV E6/E7 mRNA, we
hypothesized that ddPCR can be used for detection of
oncogenic HPV in OPSCC using oral/oropharyngeal
swabs as opposed to fresh tissue. The ability to detect
oncogenic HPV without a tissue biopsy would have
important implications for diagnosis, post-treatment
surveillance, and screening of patients with OPSCC.
The purpose of this study was to validate the use of a
novel minimally-invasive assay for detection of onco-
genic HPV based on oral/oropharyngeal swabs using
ddPCR. Our secondary objectives were to compare the
accuracy of ddPCR swabs to fresh tissue p16 IHC, and
to report the cost of ddPCR.
Methods
This was a single-center prospective cohort validation
study at a tertiary care Otolaryngology-Head and Neck
Surgery referral center in Edmonton, AB, Canada. Health
research ethics board approval was obtained from the
University of Alberta prior to commencement of the study
(Pro00057994).
Participants
Participants were recruited at initial presentation to the
University of Alberta Otolaryngology-Head and Neck
Surgery Clinic between February 2015 and March 2016.
Adult patients with biopsy-confirmed oral cavity or
oropharyngeal squamous cell carcinoma (OC/OPSCC)
were identified. Patients who had previous treatment for
HNSCC, those that were unable to undergo an oropha-
ryngeal swab, patients for which pathology report or p16
IHC was unavailable, patients with unknown primary
tumours, and improperly processed samples were ex-
cluded. The reason for including OCSCC patients in
addition to OPSCC was to be able to compare ddPCR
and p16 in a subgroup of patients for which p16 is an
especially poor marker of HPV infection, in order to
determine the enhanced specificity of ddPCR for HPV
oncogenesis.
The control group was recruited from patients who
were being consented for tonsillectomy for a benign in-
dication (ex: recurrent tonsillitis or obstructive sleep
apnea). Patients were excluded from the control group if
they had a previous history of HNSCC.
Oral/oropharyngeal swabs
Each participant underwent an oral/oropharyngeal swab
using a 10 cm cotton-tip applicator by a staff Oto-
laryngologist (VB, HS, JH, or DO). Two swabs were
performed on each patient. For patients with a clinically
evident oral/oropharyngeal tumour, one swab was taken
from the tumour, and the second swab was taken from
the oropharynx (a single swab that was brushed against
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the tonsils, base of tongue, soft palate, and posterior
pharyngeal wall subsites). For control patients, two
swabs were taken both from the oropharyngeal subsites
listed above (each swab was brushed against all of the
subsites listed above). The swab tips were immediately
placed in 3 mL of RNAlater (Ambion-Thermo Fisher
Scientific, Waltham, MA, USA) and stored at room
temperature (RT) for up to 24 h, then at 4 °C for up to
7 days prior to RNA extraction.
Tissue pathology and p16 IHC
Each patient with an oral/oropharyngeal tumour under-
went pan-endoscopy with biopsy of the tumour as per
standard clinical practice. Pathology was reported by a
head and neck pathologist at the University of Alberta to
confirm the diagnosis of SCC. p16 IHC was performed
on representative 4 μm sections cut from formalin-fixed,
paraffin-embedded tissue blocks using a monoclonal
antibody to p16, as per established guidelines [29]. For
control patients, tonsil specimens were sent for patho-
logic analysis at the time of tonsillectomy and were
interpreted by an anatomic pathologist at the University
of Alberta to confirm the diagnosis of non-malignant
tonsil tissue. P16 was not performed if the tissue was
deemed benign, since the significance of p16 in the
absence of carcinoma is unclear. Instead, these patients
were used as negative controls.
RNA extractions and cDNA synthesis
RNA was extracted from tumor tissue using the RNeasy
Mini Kit (Qiagen, Germantown, MD, USA) following
the manufacturer’s protocol. Salivary swab samples were
vortexed in 15 mL conical tubes containing 3 mL of
RNAlater and centrifuged at 3000 x g for 10 min. The
RNAlater was then aspirated and cell pellet was re-
suspended in 350 μL of buffer RLT containing 40 mM
DTT. RNA was eluted from the mini column with 35 μL
of RNAse free water. RNA concentration was quantified
using the Qubit RNA HS assay kit on a Qubit 2.0
fluorometer.
Extracted RNA (100–200 ng) was used to synthesize
cDNA using the iScriptTM Reverse Transcription Super-
mix for RT-qPCR (BIO-RAD) as per the manufacturer’s
protocol. Following the reaction the cDNA was diluted
with 0.125 mM EDTA pH 8.0 to 0.5 ng/μl and either
stored at −20 °C or used directly for ddPCR.
Droplet digital PCR
All ddPCR reactions were performed by MK, who was
blinded to the patient group, pathology, and p16 IHC
status of participant samples. ddPCR was carried out
using the ddPCRTM Supermix for Probes (No dUTP)
(BIO-RAD, Mississauga, ON, CAN), the QX200TM
Droplet Generator (catalog #186-4002 BIO-RAD), the
QX200 Droplet Reader (catalog #186-4003 BIO-RAD) the
C1000 TouchTM Thermal Cycler (catalog #185-1197
BIO-RAD) and the PX1TM PCR Plate Sealer (catalog
#181-4000 BIO-RAD) as per manufacturer’s instructions.
Reactions were set up following the manufacturer’s proto-
cols using 12 μl/reaction of 2x ddPCR Supermix for
Probes (No dUTP), 1.2 μL/reaction of 20x target primers/
probe (FAM or HEX, BIO-RAD), 1.2 μL/reaction 20x
reference primers/probe (FAM or HEX, BIO-RAD),
2.4 μL cDNA (at 0.5 ng/μl) and 7.2 μl H2O. Human EEF2
primers/probes (BIO-RAD) were used as an internal
reference standard and indirect indicator of nucleic acid
stability in participant samples. HPV E6 and E7 ddPCR
detection was performed using the following primer/probe
sequences generated by BIO-RAD [30], adapting primer
sequences from HPV E6: forward sequence, 5′-TCAGG
ACCCACAGGAGCG-3′, reverse sequence, 5′-CCTCA
CGTCGCAGTAACTGTTG-3′, probe (FAM-labeled) se-
quence, 5′-CAGAAAGTTACCACAGTTATGCACAGA
GCT-3′. HPV E7: forward sequence, 5′-CCGGACAGA
GCCCATTACAA -3′, reverse sequence, 5′-CGAATGT
CTACGTGTGTGCTTTG -3′, probe (HEX-labeled)
sequence, 5′-CGCACAACCGAAGCGTAGAGTCACAC
T -3′. Reactions were set up in a 96 well plate, mixed
using a Mixmate Vortex Shaker (Eppendorf, Mississauga,
ON, CAN) and 20 μl of the reaction mixture was trans-
ferred to DG8TM Cartridge for QX200/QX100 Droplet
Generator (catalog #186-4008 BIO-RAD) followed by
70 μl of Droplet Generation Oil for Probes (catalog
#186-3005 BIO-RAD) into the oil wells, according to
the QX200 Droplet Generator Instruction Manual
(#10031907 BIO-RAD). Following droplet generation,
40 μL of the reaction was transferred to wells of a 96
well plate. The plates were sealed and the reactions
were carried out in the thermocycler using the follow-
ing parameters: Step 1) 95 °C for 10 min, Step 2) 94 °C
for 30 s and 60 °C for 1 min (Step 2 repeat 39 times for
a total of 40), Step 3) 98 °C for 10 min and Step 4) 4 °C
infinite hold. All steps had a ramp rate of 3 °C/s. Fol-
lowing thermocycling the reactions were read in the
QX200 Droplet Reader and the RNA targets were
quantified using the QuantaSoftTM Software (BIO-
RAD). HPV E6 and E7 positivity was determined using
automated cutoff values relative to control as previ-
ously described [28]. Samples with > 2 droplets in the
positive range for E6 or E7 were considered positive.
Samples with < 20 positive droplets were re-analyzed to
ensure these low copy number samples were not due to
cross-contamination.
Validation of ddPCR sensitivity against RT-qPCR
As previously shown in other studies, we confirmed the
enhanced sensitivity of ddPCR over RT-qPCR using
decreasing concentrations of target RNA for EEF2 and
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E7 (see Additional file 1: Table S1). As recommended by
the manufacturer (BioRAD), the same EEF2 and E7 pri-
mer/probe sets used in ddPCR were used for qRT-PCR
with optimized annealing temperatures. RT-qPCR was
performed as follows: RNA (100 ng) was used to
synthesize cDNA using the iScriptTM Reverse Tran-
scription Supermix for RT-qPCR (BIO-RAD) as per the
manufacturer’s protocol in a 20 ul reaction. The result-
ing cDNA was diluted to 1.25 ng/ul, 0.125 ng/ul and
0.0125 ng/ul with water and these dilutions were used to
load 10 ng, 1.0 ng and 0.1 ng respectively into reaction
wells for either the qPCR or ddPCR. 20 ul final qPCR
reactions were set up following the manufacturer’s pro-
tocols using 10 ul/reaction of 2x iTaqTM Universal
Probes Supermix (BIO-RAD), 1 ul/reaction of 20x target
primers/probe (FAM or HEX, BIO-RAD), 1 ul/reaction
20x reference primers/probe (FAM or HEX, BIO-RAD)
and 8 ul of cDNA. Reactions were carried out in the
CFX96 Touch™ Real-Time PCR Detection System using
the “Prime PCR” Manufacturer’s program with the
following parameters: Step 1) 95 ° C for 2 min, Step 2)
95 ° C for 5 s and 60 ° C for 30 s (Step 2 repeat 39 times
for a total of 40), Step 3) 95 ° C for 5 s.
Data analysis
Descriptive statistics were performed to determine the
proportion of patients recruited with p16 positive vs.
negative OC/OPSCC. Agreement between ddPCR and
p16 IHC was determined for patients with p16 positive
and negative OC/OPSCC as well as for healthy control
patients. The sensitivity and specificity of ddPCR of
oropharyngeal swabs were calculated against p16 IHC
for OPSCC.
Results
122 patients met the inclusion and exclusion criteria and
were prospectively enrolled in the study. These patients
are summarized in Table 1. There were 36 patients with
p16 positive OPSCC (p16+OPSCC), 16 patients with p16
negative OPSCC (p16−OPSCC), 4 patients with p16
+OCSCC, and 41 patients with p16−OCSCC. 25 patients
were healthy controls. The mean concentration of RNA
obtained from oral/oropharyngeal swabs was 5.31 μg/mL
(range 2.2-12.1 μg/mL). The minimum target RNA
required per reaction was ≤1 ng.
33/36 (92%) of patients with p16+OPSCC tested posi-
tive for E6/E7 by ddPCR (Table 2). One patient with p16
−OPSCC tested positive for E6/E7 by ddPCR. The se-
nsitivity of ddPCR of oropharyngeal swabs against fresh
tissue p16 IHC was 92%. All 4 patients with p16
+OCSCC tested negative for E6/E7 by ddPCR, as did all
41 patients with p16−OCSCC (Table 3). All 25 healthy
control patients tested negative for E6/E7 by ddPCR, for
an overall specificity of 98% for OPSCC. The agreement
between ddPCR and p16 via unweighted kohen’s kappa
was ĸ = 0.826 [0.662-0.989]
The cost of p16 IHC across the province of Alberta is
$31.10/slide, with a minimum of 2 slides required per
patient (≥ $62.10/patient). In comparison, the total cost
of HPV E6/E7 ddPCR including technical labour was
estimated to be $20.45 per patient sample.
Discussion
The incidence of HPV-related OPSCC is rapidly growing
and poses challenges for diagnosis and management.
Accurate determination of HPV status in patients with
OPSCC is therefore critical. Performing HPV testing
using a method that is cost effective and minimally inva-
sive while maintaining adequate sensitivity has many
potential applications. The method presented here is to
our knowledge the most sensitive method of diagnosing
oncogenic HPV mRNA without a tissue biopsy reported
to date. Every swab performed in this study yielded
adequate RNA for amplification, with 1 ng of RNA/reac-
tion required for robust ddPCR results. This is an order
of magnitude less than the 20–50 ng/reaction of RNA
that is normally required for RT-qPCR [30–33]. This is
also to our knowledge the first study to compare non-
invasive oncogenic HPV detection with the clinical refer-
ence standard of p16 IHC. In addition to the greater
specificity of using an HPV-specific assay, our cost
Table 1 Patient demographics and diagnoses
Patient Variable Number of patients (%) n = 122
Mean Age ± SD 57 ± 15 years
Males 74 (67%)
Oropharyngeal SCC p16 + 36 (30%)
p16 - 16 (13%)
Oral Cavity SCC p16 + 4 (3%)
p16 - 41 (34%)




Smoking History (all patients) 46 (38%)
Normal tonsil 25 (20%)
SCC squamous cell carcinoma
Table 2 p16 IHC and ddPCR E6/E7 Results in Patients with OPSCC
p16 + p16 - Totals
ddPCR + 33 1 34
ddPCR - 3 15 18
Totals 36 16
IHC immunohistochemistry, ddPCR droplet digital polymerase chain reaction,
OPSCC oropharyngeal squamous cell carcinoma
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analysis demonstrates a significant cost-savings of ddPCR
over p16 IHC for determining HPV status in OPSCC.
Overall our results demonstrated excellent sensitivity
in detecting oncogenic HPV in oropharyngeal swabs
without a biopsy, as 92% of p16+OPSCC tested positive
by ddPCR. The three patients with p16+OPSCC that
tested negative for E6/E7 by ddPCR may in fact highlight
the limitations of p16 IHC as a surrogate marker for
HPV, as these three patients were older and had signifi-
cant smoking and alcohol use histories, and thus may
have had disease that was unrelated to HPV. While stud-
ies have suggested that p16 is itself an important prog-
nostic marker independent of HPV infection in OPSCC
[13, 34], others have questioned the prognostic utility of
p16 in HPV negative tumors [35], and have demon-
strated improved prognostication when HPV-specific
tests are used [36]. Robinson et al. argued that HPV-
specific testing remains essential in OPSCC regardless of
p16 status [37].
Our results also demonstrated a high degree of accur-
acy in determining HPV status in OCSCC, as all 4 pa-
tients with p16+OCSCC tested negative for E6/E7 by
ddPCR. Other studies have shown that non-OPSCC that
are p16 positive are usually unrelated to HPV, and that
p16 positivity does not purport a better prognosis in
non-OPSCC, and may in fact yield a worse prognosis in
these patients [38–41]. This adds to the clinical utility of
using HPV-specific ddPCR as opposed to or in addition
to p16 IHC in both OPSCC and non-OPSCC.
The fact that the assay we have described yielded
excellent sensitivity without the need for a tissue biopsy
has several important implications, the most immedi-
ately relevant of which may be for post-treatment sur-
veillance. One recent study claimed to be able to predict
recurrence of OPSCC earlier using salivary rinses for
detection of oncogenic HPV [42], however this assay
was limited by a lack of sensitivity due to the large
amount of RNA required for RT-qPCR. A similarly
designed study by Chuang et al. reported a sensitivity of
50% in predicting recurrent OPSCC using oral rinses for
HPV DNA using RT-qPCR, although this study only
included 4 patients with recurrent OPSCC [43]. Ahn et
al. also used oral rinses for HPV DNA to predict
recurrent OPSCC and found that when combined with
plasma RT-qPCR, a sensitivity of almost 70% could be
achieved; however, the pre-treatment sensitivity of oral
rinses was only 53% [30]. With the significantly im-
proved sensitivity of the novel assay we have described,
post-treatment surveillance may be more effective using
regular oropharyngeal swabs to detect E6/E7 via ddPCR.
The use of ddPCR for post-treatment surveillance needs
further research however before this can be recom-
mended or widely utilized.
Other studies that have attempted to determine HPV
status using oral rinses and various PCR-based assays in a
diagnostic fashion as opposed to post-treatment surveil-
lance have reported similarly low sensitivities. Both Zhao et
al. and Nordfors et al. compared RT-qPCR in oral rinses
with tissue biopsies in patients with OPSCC and reported
sensitivities of 30 and 68% respectively for HPV 16 DNA
[44, 45]. With the improved sensitivity provided by our
ddPCR-based assay, clinicians may be able to use the infor-
mation diagnostically to make a diagnosis of HPV-related
OPSCC sooner. This is particularly useful in settings where
a biopsy may be difficult to obtain, or as part of the work-
up for an unknown primary tumor. Moreover, with the
rising prevalence of HPV-related OPSCC, our ddPCR assay
may be a viable mode of screening high-risk patient groups
for early detection or prevention of OPSCC in the future.
Fahkry et al. attempted to validate a “cervical pap smear-
equivalent” test for early detection of HPV-related OPSCC
using a combination of oral rinses and tonsillar brush
biopsies via RT-qPCR; however, they concluded that it
was not feasible due to the lack of correlation between
HPV DNA detection and cellular atypia [46]. The authors
postulated that this was due to the difficulty in detecting
HPV DNA that may be replicating deep within the tonsil-
lar crypt epithelium, a problem that could potentially be
solved by an ultra-sensitive ddPCR-based assay.
This study had limitations, which included a single center
experience and a relatively small sample size especially for
p16+OCSCC and p16−OPSCC. Our sensitivity and specifi-
city data also need to be interpreted cautiously, as these
were calculated against the results of p16 IHC, which is
itself known to be a surrogate marker; however, our aim
was to demonstrate the sensitivity of a swab-based assay
against the mostly widely-used tissue-based assay for deter-
mining HPV status. We also only tested for HPV 16 as in
other studies; however, HPV 16 is known to cause more
than 95% of HPV-related OPSCC [46]. We plan to expand
our assay to test for HPV 18 in addition to HPV 16.
Conclusion
Oropharyngeal swabs analyzed by ddPCR is a quantita-
tive, rapid, and cost-effective method for minimally
invasive oncogenic HPV detection. This assay represents
the most sensitive and accurate mode of HPV detection
in OPSCC without a tissue biopsy in the available
literature, and has several potential applications for both
diagnosis and disease surveillance.
Table 3 p16 IHC and ddPCR E6/E7 Results in Patients with OCSCC
p16 + p16 - Totals
ddPCR + 0 0 0
ddPCR - 4 41 45
Totals 4 41
IHC immunohistochemistry, ddPCR droplet digital polymerase chain reaction,
OCSCC oral cavity squamous cell carcinoma
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